BackBiotechnologies Assets S.A. Overview

Biotechnologies Assets S.A. Current Cash

Track Biotechnologies Assets S.A.'s current cash ($420K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$422474.00
↑ 193.75% YoYΔ $278652.00 vs prior year quarter

Peer trimmed avg / median

Loading

Biotechnologies Assets S.A. Current Cash History

Loading

Biotechnologies Assets S.A. vs. peers: Current Cash Comparison

Loading

Biotechnologies Assets S.A. Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Biotechnologies Assets S.A. (BST.MC) FAQ

The latest current cash for BST.MC is $420K as of December 2025. That compares with $140K in the prior-year period — up 193.7% year over year. Investors often review this figure alongside Biotechnologies Assets S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BST.MC's current cash moved from $140K to $420K — a 193.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biotechnologies Assets S.A.'s operating scale or balance-sheet position.

A current cash figure of $420K for BST.MC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BST.MC's current cash ($420K), review year-over-year change from $140K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Biotechnologies Assets S.A.'s current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.